西隴科學(002584.SZ)2021年度淨利潤預增169%-252%
格隆匯1月25日丨西隴科學(002584.SZ)公佈,預計2021年度歸屬於上市公司股東的淨利潤1.53億元-2億元,同比增長169%-252%;扣除非經常性損益後的淨利潤5000萬元–7500萬元,同比增長252%-429%。業績變動原因如下:
1、報吿期內業績變動主要原因系公司轉讓控股子公司福建福君基因生物科技有限公司部分股權,取得收益約人民幣1.05億元,非經常性收益較上年約增加7000萬元(未經審計)。
2、報吿期內,公司扣除非經常性損益後的淨利潤較去年同期增長252%-429%,主要原因是受市場供求關係等多種因素的影響,部分化工產品價格上漲;公司積極抓住市場機遇,營業收入同比上升;同時提升經營效率,淨利潤增加。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.